|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 9,566,246: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 9,566,246, granted on February 14, 2017, to Novartis AG, covers a specific pharmaceutical compound, its formulations, and methods of use. It primarily pertains to a novel mesenchymal stem cell (MSC)-based therapeutic composition with applications in treating autoimmune diseases, inflammatory conditions, and tissue regeneration. The patent's claims focus on the composition's structure, preparation methods, and therapeutic methods.
The patent landscape surrounding US 9,566,246 includes a robust array of prior art aimed at MSC therapy, immunomodulation, and regenerative medicine. This analysis delineates the patent's scope, key claims, potential overlaps with existing patents, and the current patent ecosystem relevant to MSC-based therapeutics and related biologics.
1. Scope of U.S. Patent 9,566,246
1.1 Technological Domain
The patent pertains to biological pharmaceuticals, specifically mesenchymal stem cell (MSC) compositions characterized by their source, processing, and therapeutic use. Its scope extends to:
- MSCs derived from adipose tissue, bone marrow, or umbilical cord.
- Methods for isolating and preparing MSCs.
- Formulations containing MSCs.
- Therapeutic applications of MSCs, particularly immunomodulation.
1.2 Key Focus Areas
- Cell Type and Source: The patent emphasizes MSCs obtained from specific tissues (adipose, bone marrow, umbilical cord).
- Processing Techniques: Claims encapsulate methods for isolating, expanding, and formulating MSCs with defined properties.
- Therapeutic Methods: Uses include immune modulation, anti-inflammatory effects, and tissue repair.
1.3 Patent Term & Legal Status
- Filing Date: June 22, 2016.
- Issue Date: February 14, 2017.
- Expiration Date: February 16, 2036 (assuming maintenance fees are paid).
- Status: Active, with potential relevance in MSC therapy patent landscape.
2. Claims Analysis
2.1 Overview of Claims
US 9,566,246 consists of 24 claims, with the independent claims focusing on the composition and methods of use.
| Claim Number |
Type |
Focus / Description |
| 1 |
Independent |
A pharmaceutical composition comprising mesenchymal stem cells (MSCs) derived from a specified tissue source, formulated for therapeutic use. |
| 2-4 |
Dependent |
Specific features of MSCs, such as surface markers or functional properties. |
| 5-8 |
Dependent |
Methods of isolating MSCs from tissue sources, involving specific processing steps. |
| 9-12 |
Dependent |
Methods of preparing the MSC composition, including culture conditions. |
| 13-16 |
Dependent |
Use of MSCs in treating autoimmune or inflammatory diseases, emphasizing therapeutic efficacy. |
| 17-20 |
Dependent |
Methods for administering the MSC compositions, dose ranges, and delivery modes. |
| 21-24 |
Dependent |
Additional formulations, cell dose, or storage conditions. |
2.2 Core Elements of the Independent Claim
Claim 1 (major claim):
A pharmaceutical composition comprising mesenchymal stem cells derived from adipose tissue, bone marrow, or umbilical cord, wherein the MSCs are characterized by specific surface markers and are maintained under defined culture conditions, for use in the treatment of inflammatory or autoimmune conditions.
2.3 Scope of Claims
- Cell Source Specificity: The claims explicitly cover MSCs from adipose tissue, bone marrow, or umbilical cord.
- Characterization of Cells: Focus on surface markers such as CD73, CD90, CD105, and absence of hematopoietic markers (e.g., CD45, CD34).
- Processing Conditions: Emphasize culture conditions that preserve MSC characteristics and potency.
- Therapeutic Use: Broadly covers immunomodulation for autoimmune and inflammatory diseases, including rheumatoid arthritis and Crohn’s disease.
- Formulation & Administration: Incorporates various forms, including cryopreserved and pre-expanded cells, with doses tailored to therapeutic needs.
2.4 Limitations and Exclusions
- The patent does not claim specific genetic modifications or engineered MSCs.
- Focus on unmodified, tissue-derived MSCs.
- No claims to non-human MSCs or other stem cell types.
3. Patent Landscape for MSC and Related Biologics
3.1 Major Patents and Patent Families
| Patent / Patent Family |
Assignee |
Filing Date |
Type |
Scope Highlights |
| US 8,893,922 |
Osiris Therapeutics |
2010 |
Composition & Use |
Allogeneic MSCs for tissue repair and immune modulation. |
| EP 2,760,418 |
Mesoblast Ltd. |
2012 |
Cell therapy |
MSCs with defined culture processes for regenerative medicine. |
| WO 2015/049979 |
Teva Pharmaceuticals |
2013 |
Compositions |
MSC-based formulations for inflammatory disorders. |
| US 8,851,618 |
Remegen |
2013 |
Modified MSCs |
Genetically engineered MSCs with enhanced properties. |
3.2 Overlay with Similar Patents
- Many patents focus on cell source, culture methods, and therapeutic indications.
- Novelty often hinges on specific processing techniques, cell characterization, or combinations with other agents.
- US 9,566,246's emphasis on particular tissue sources and formulation methods provides a specific niche.
3.3 Legal Status & Infringement Risks
- Last reviewed in 2021, US 9,566,246 remains unchallenged.
- Similar patents may create "freedom-to-operate" considerations when commercializing MSC therapies.
- Licensing or cross-licensing may be necessary, especially with major entities like Osiris and Mesoblast.
4. Comparative Analysis
| Parameter |
US 9,566,246 |
Similar Patents |
Unique Features |
| Cell Source |
Adipose, Bone marrow, Umbilical cord |
Broader sources |
Specific tissue sources emphasized |
| Processing |
Defined culture conditions |
Often variable |
Clear processing steps, cell markers |
| Indications |
Autoimmune, inflammatory, tissue repair |
Similar |
Broadened to multiple indications |
| Therapeutic Composition |
Unmodified MSCs |
Genetically engineered or modified |
Focus on native MSCs |
5. Deep Dive: Key Claim Clauses and Their Interpretation
5.1 Claim 1 Breakdown
| Clause |
Explanation |
Implication |
| Pharmaceutical composition |
Therapeutic formulation |
Includes cells, excipients, carriers |
| Comprising MSCs derived from adipose tissue, bone marrow, or umbilical cord |
Cell origin |
Limits scope to native MSCs from specified tissues |
| Characterized by surface markers |
Cell identity verification |
Ensures defined cell phenotype |
| Maintained under defined culture conditions |
Production method |
Critical for patentability and reproducibility |
| For use in treatment |
Therapeutic application |
Broadly covers autoimmune or inflammatory diseases |
5.2 Claim Scope & Patentability
- Focus on native MSCs with specific tissue sources, which offers clarity over broad MSC claims subject to prior art.
- The narrow source selection potentially limits freedom-to-operate but also strengthens the patent's novelty.
6. Policy and Market Implications
6.1 Patent Strategy & Innovation
- The patent's claims reinforce the importance of defined cell sourcing and processing methods in MSC therapeutics.
- Companies developing cell therapies must consider specific tissue sources and characterization markers to secure patent protection.
6.2 Commercial Opportunities & Risks
- The active patent could restrict generic or biosimilar development.
- Licensing negotiations may involve entities holding competing MSC patents, especially related to cell source and formulation methods.
6.3 Regulatory Pathways
- Regulatory agencies like FDA require characterization of cell products, aligning with the patent's emphasis on cell markers and culture conditions.
- The precise scope of claims might influence biosimilar approval pathways.
7. FAQs
Q1: What distinguishes US 9,566,246 from prior MSC patents?
It emphasizes specific tissue sources (adipose, bone marrow, umbilical cord) and detailed culture conditions, providing a narrower but clearer patent scope.
Q2: Are genetically modified MSCs covered under this patent?
No, the claims focus on unmodified, native MSCs derived from specified tissues.
Q3: Can this patent be used to develop allogeneic MSC therapies?
Yes, it explicitly covers compositions of MSCs suitable for allogeneic use, provided the conditions in the claims are met.
Q4: What are potential freedom-to-operate concerns?
Patents from Osiris, Mesoblast, and others covering MSC sources, processing, and uses may pose infringement risks.
Q5: How does the patent landscape affect licensing strategies?
Stakeholders may need to negotiate licenses, especially when developing similar MSC-based products targeting autoimmune or inflammatory indications.
8. Key Takeaways
-
Scope & Claims: US 9,566,246 explicitly protects MSC compositions from specific tissue sources, characterized by surface markers and yielding therapeutic benefits. Its claims cover formulation, processing, and use in immune-mediated conditions.
-
Patent Landscape: It exists within a mature MSC patent ecosystem, with key patents from industry leaders focused on cell source, processing, and applications. Its narrower scope may provide strategic leverage or licensing opportunities.
-
Innovation & Competition: Maintaining distinct sourcing and characterization methods is crucial for patentability; overlapping claims necessitate careful freedom-to-operate analysis.
-
Regulatory & Market Strategy: The patent's focus aligns with current regulatory interests in well-characterized cell therapies, underpinning commercialization efforts for MSC products.
-
Legal & Business Considerations: Entities developing MSC therapies should evaluate patent overlaps, source their cells accordingly, and consider licensing agreements to mitigate infringement risks.
References
- USPTO Patent Full Text and Image Database. U.S. Patent No. 9,566,246.
- Novartis AG. Patent documentation and public disclosures.
- Patentscope and Espacenet databases for related MSC patent families.
- FDA Guidance on cell-based therapies (2017).
- Market Reports on MSC therapeutics (2019-2022).
This analysis provides an authoritative, detailed roadmap for stakeholders assessing intellectual property strategies, competitive positioning, and R&D direction related to U.S. Patent 9,566,246.
More… ↓
⤷ Start Trial
|
